80 results
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated
Results From Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability … and safety profile. We plan to report data on histologic changes assessed after 52 weeks of treatment later this quarter. Finally, during the first
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
, at potentially higher doses, may result
in additional weight loss. We are particularly pleased with the initial safety and tolerability data, which suggest … ) Two-sided t test using mixed model for repeated measures. 6) Fisher’s exact test.
Safety and Tolerability
Oral VK2735 demonstrated encouraging safety
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
4 Mar 24
Other Events
4:52pm
subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company
424B5
VKTX
Viking Therapeutics Inc
1 Mar 24
Prospectus supplement for primary offering
4:13pm
the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3. The primary endpoint … -controlled, SAD and MAD study in healthy adults. The primary objectives of the study included evaluation of the safety and tolerability of single and multiple
8-K
EX-1.1
yt59kgtzp2lpx406e
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
8-K
EX-99.1
tj0rcvcfhseyg dkeey
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
0jio4n4s
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
ivscvs9pywpfoj60gzb2
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
8g5cxynfvj
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
skvixy8zn8
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
93o00 8qb47uhy
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
m8df5ky
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-3.1
tz6723tlyplfl pr
11 May 23
Amendments to Articles of Incorporation or Bylaws
5:00pm
8-K
EX-99.1
l167vatz2jpnz5l4yr5
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-1.1
rczjdhqbl8dc93eqh
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm